ADVERTISEMENT
Gland Pharma Q3 Results Review - Motilal Oswal Reiterates 'Buy' On New Launches, Higher Milestone Income
Cenexi's performance was adversely affected by a surprise inspection of French health authorities and a lyophilizer breakdown, adds the brokerage.
04 Feb 2025, 11:10 AM IST 
Gland Pharma Ltd. delivered a better-than-expected operating performance for the quarter.
(Photo source: Company website)
The brokerage values Gland Pharma at 28x 12 months (versus 30 times earlier) forward earnings to arrive at target price of Rs 1,840. The reduction in multiple is to factor in slower execution in core business as well as Cenexi.
